lorlatinib-resistant ALK mutants don't bind lorlatinib

Stable Identifier
R-HSA-9715355
Type
Reaction [FailedReaction]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

The following ALK mutants are resistant to inhibition by lorlatinib:

ALK I1171N: Ouseph et al, 2019
ALK I1171S: Takahashi et al, 2020
ALK L1196M: Yoda et al, 2018
ALK L1198F: Yoda et al, 2018
ALK G1202R: Kougioumtzi et al, 2019
ALK G1269A: Kougioumtzi et al, 2019; Takahashi et al, 2020; Yoda et al, 2018

Literature References
PubMed ID Title Journal Year
31943796 Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer

Uchibori, K, Yanagitani, N, Tsukahara, M, Okubo, K, Nishio, M, Seto, Y, Okada, K, Takahashi, K, Oh-Hara, T, Uematsu, S, Fujita, N, Katayama, R

Thorac Cancer 2020
31616196 TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations

Patel, NR, Khurshid, H, Ali, SM, Aswad, BI, Resnick, MB, Yakirevich, E, Ouseph, MM, Taber, A, Madison, R

Lung Cancer (Auckl) 2019
29650534 Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

Mino-Kenudson, M, Friboulet, L, Benes, CH, Engelman, JA, Yoda, S, Gainor, JF, Dardaei, L, Iafrate, AJ, Heist, RS, Shaw, AT, Dagogo-Jack, I, Langenbucher, A, Burke, BJ, Hata, AN, Ferris, LA, Timonina, D, Johnson, TW, Hubbeling, H, Timofeevski, S, Lawrence, MS, Kattermann, KE, Lin, JJ, Prutisto-Chang, K, Riley, AK, Lennerz, JK

Cancer Discov 2018
31749991 Molecular findings reveal possible resistance mechanisms in a patient with ALK-rearranged lung cancer: a case report and literature review

Kampletsas, E, Ntellas, P, Nasioulas, G, Papadopoulou, E, Kougioumtzi, A, Pentheroudakis, G

ESMO Open 2019
Participants
Participates
Normal reaction
Functional status

Loss of function of lorlatinib-resistant ALK mutants [plasma membrane]

Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!